A Double-Blind, Randomized, Placebo Controlled, Cross-Over, Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2012
At a glance
- Drugs Dasolampanel (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 16 Nov 2009 Results will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held 20-21 Nov 2009, according to a Raptor Pharmaceutical Corp media release.
- 06 Jun 2008 New trial record.
- 05 Jun 2008 Status changed from not yet recruiting to recruiting, reported in a TorreyPines media release.